Vyome Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $14.3M
- Price
- $2.04
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.97%
- Volume
- 11.4K
About
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Quick stats
Shares outstanding7.0M
Computed float5.2M
Float / shares74.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001427570
Websitehttps://www.vyometx.com
AI Summary
AI-generated1/9
minorbullishoperations update
Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market
Vyome Holdings received a USPTO Notice of Allowance for a U.S. patent covering formulations and methods of use for VT-1908, its topical ophthalmic mycophenolate program initially targeting anterior uveitis.
Preclinical results published in a peer-reviewed Springer Nature journal showed steroid-comparable efficacy in a uveitis model, supporting continued development as a steroid-sparing therapy.
The company estimates the broader ocular inflammation market at more than $20 billion by 2035; the program remains preclinical, so no revenue or clinical milestones are yet at stake.
Red flags
- VT-1908 is preclinical; patent allowance does not de-risk clinical or regulatory development
- Patent could still be narrowed, challenged, or circumvented per forward-looking statement caveats
- $20B+ market estimate is company-sourced from third-party market research